4//SEC Filing
Ordentlich Peter 4
Accession 0001562180-22-008017
CIK 0001395937other
Filed
Dec 1, 7:00 PM ET
Accepted
Dec 2, 5:01 PM ET
Size
19.4 KB
Accession
0001562180-22-008017
Insider Transaction Report
Form 4
Ordentlich Peter
Chief Technology Officer
Transactions
- Exercise/Conversion
Common Stock
2022-12-02$6.38/sh+17,200$109,736→ 17,465 total - Exercise/Conversion
Common Stock
2022-12-01$6.35/sh+3,772$23,952→ 4,037 total - Exercise/Conversion
Common Stock
2022-12-01$6.38/sh+4,028$25,699→ 4,293 total - Sale
Common Stock
2022-12-01$25.01/sh−4,028$100,746→ 265 total - Exercise/Conversion
Stock Options (Right to buy)
2022-12-01−4,028→ 0 totalExercise: $6.38Exp: 2029-02-06→ Common Stock (4,028 underlying) - Exercise/Conversion
Stock Options (Right to buy)
2022-12-02−17,200→ 0 totalExercise: $6.38Exp: 2029-02-06→ Common Stock (17,200 underlying) - Sale
Common Stock
2022-12-01$25.01/sh−3,772$94,343→ 265 total - Sale
Common Stock
2022-12-02$25.05/sh−17,200$430,936→ 265 total - Exercise/Conversion
Stock Options (Right to buy)
2022-12-01−3,772→ 0 totalExercise: $6.35Exp: 2024-12-18→ Common Stock (3,772 underlying)
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 255,925 options to purchase shares of common stock that are vested and immediately exercisable and a total of 122,916 options to purchase shares of common stock that have not yet vested.
- [F2]The sale prices ranged from $25.00 to $25.03.
- [F3]The sale prices ranged from $25.00 to $25.19.
- [F4]This option is fully vested.
Documents
Issuer
Syndax Pharmaceuticals Inc
CIK 0001395937
Entity typeother
Related Parties
1- filerCIK 0001594274
Filing Metadata
- Form type
- 4
- Filed
- Dec 1, 7:00 PM ET
- Accepted
- Dec 2, 5:01 PM ET
- Size
- 19.4 KB